dc.creator | Palazón Carrión, Natalia | es |
dc.creator | Martín García-Sancho, Alejandro | es |
dc.creator | Nogales-Fernández, Esteban | es |
dc.creator | Jiménez Cortegana, Carlos | es |
dc.creator | Carnicero-González, Fernando | es |
dc.creator | Ríos Herranz, Eduardo | es |
dc.creator | Sánchez Margalet, Víctor | es |
dc.creator | Rueda Domínguez, Antonio | es |
dc.creator | Cruz Merino, Luis de la | es |
dc.date.accessioned | 2023-05-18T13:13:11Z | |
dc.date.available | 2023-05-18T13:13:11Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Palazón Carrión, N., Martín García-Sancho, A., Nogales-Fernández, E., Jiménez Cortegana, C., Carnicero-González, F., Ríos Herranz, E.,...,Cruz Merino, L.d.l. (2022). Lenalidomide plus R-GDP (R2-GDP) in Relapsed/ Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis. CLINICAL CANCER RESEARCH, 28 (17), 3658-3668. https://doi.org/10.1158/1078-0432.CCR-22-0588. | |
dc.identifier.issn | 1078-0432 | es |
dc.identifier.issn | 1557-3265 | es |
dc.identifier.uri | https://hdl.handle.net/11441/146355 | |
dc.description.abstract | Purpose: New therapeutic options are needed in relapsed/refrac tory diffuse large B-cell lymphoma (R/R DLBCL). Lenalidomide based schedules can reverse rituximab refractoriness in lymphoma.
Patients and Methods: In the phase II R2-GDP trial, 78
patients unsuitable for autologous stem cell transplant received
treatment with the following schedule: lenalidomide 10 mg Days
(D)1–14, rituximab 375 mg/m2 D1, cisplatin 60 mg/m2 D1,
gemcitabine 750 mg/m2 D1 and D8, and dexamethasone 20 mg
D1–3, up to 6 cycles (induction phase), followed by lenalidomide
10 mg (or last lenalidomide dose received) D1–21 every 28 days
(maintenance phase). Primary endpoint was overall response
rate (ORR). Secondary endpoints included progression-free
survival (PFS), overall survival (OS), safety, and monitorization
of key circulating immune biomarkers (EU Clinical Trials Reg ister number: EudraCT 2014-001620-29).
Results: After a median follow-up of 37 months, ORR was
60.2% [37.1% complete responses (CR) and 23.1% partial
responses (PR)]. Median OS was 12 months (47 vs. 6 months
in CR vs. no CR); median PFS was 9 months (34 vs. 5 months in
CR vs. no CR). In the primary refractory population, ORR was
45.5% (21.2% CR and 24.3% PR). Most common grade 3–4
adverse events were thrombocytopenia (60.2%), neutropenia
(60.2%), anemia (26.9%), infections (15.3%), and febrile neutro penia (14.1%). Complete responses were associated with a sharp
decrease in circulating myeloid-derived suppressor cells and
regulatory T cells.
Conclusions: R2-GDP schedule is feasible and highly active
in R/R DLBCL, including the primary refractory population.
Immune biomarkers showed differences in responders versus
progressors. | es |
dc.description.sponsorship | Consejería de Salud y Familias. Junta de Andalucía | es |
dc.format | application/pdf | es |
dc.format.extent | 11 p. | es |
dc.language.iso | eng | es |
dc.publisher | AMER ASSOC CANCER RESEARCH | es |
dc.relation.ispartof | CLINICAL CANCER RESEARCH, 28 (17), 3658-3668. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Lenalidomide plus R-GDP (R2-GDP) | es |
dc.subject | Large B-Cell Lymphoma | es |
dc.subject | Lymphoma | es |
dc.title | Lenalidomide plus R-GDP (R2-GDP) in Relapsed/ Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Bioquímica Médica y Biología Molecular e Inmunología | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://aacrjournals.org/clincancerres/article/28/17/3658/708080/Lenalidomide-plus-R-GDP-R2-GDP-in-Relapsed | es |
dc.identifier.doi | 10.1158/1078-0432.CCR-22-0588 | es |
dc.journaltitle | CLINICAL CANCER RESEARCH | es |
dc.publication.volumen | 28 | es |
dc.publication.issue | 17 | es |
dc.publication.initialPage | 3658 | es |
dc.publication.endPage | 3668 | es |
dc.contributor.funder | Junta de Andalucía | es |
dc.contributor.funder | European Commission (EC). Fondo Europeo de Desarrollo Regional (FEDER) | es |
dc.description.awardwinning | Premio Anual Publicación Científica Destacada de la US. Facultad de Medicina | |
dc.description.awardwinning | | |
dc.description.awardwinning | Premio Mensual Publicación Científica Destacada de la US. Facultad de Medicina | |